# Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

> **Newsylist Open Intelligence Dossier** · First detected: 2026-07-27 14:29 UTC · Category: Business · Sources: 14 · Current Velocity: 14.03

## Executive Summary
Capricor Therapeutics shares have plunged after FDA staff raised concerns regarding the efficacy and data of its Duchenne heart disease therapy.

## Intelligence Brief
The FDA is questioning the efficacy and data associated with Capricor's therapy for Duchenne heart disease. These concerns were flagged by FDA staff ahead of a scheduled hearing.


Coverage from Reuters, STAT, and WTVB emphasizes the FDA's flags on the drug's efficacy. Following these reports, Reuters notes that company shares have plunged, while Yahoo Finance discusses whether the stock is now trading at a discount.


Attention remains on the upcoming hearing. Additionally, MarketBeat reports that stock traders have purchased a large volume of call options on Capricor Therapeutics (NASDAQ:CAPR).

## Verified Facts & Key Claims
### What is the FDA's primary concern regarding Capricor?
FDA staff have flagged concerns regarding the efficacy and data of the company's Duchenne heart disease therapy.

### How has the market reacted to the FDA news?
Shares of Capricor Therapeutics have plunged, though MarketBeat reports a large volume of call options have been purchased by traders.

### When did these concerns emerge?
The concerns were raised ahead of a scheduled hearing.

## Key People, Organizations & Locations
FDA, Ahead, Duchenne, Capricor, Stock Traders Purchase Large Volume of Call Options, Capricor Therapeutics, Is Capricor Therapeutics CAPR Trading At A Discount After Its Lease Deal And FDA Wait

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Moomoo | Roth Capital Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $7 From $38 | 2026-07-27 23:18 | [Source Link](https://news.google.com/rss/articles/CBMitgFBVV95cUxNYXNWRGQ2ajI3TXB5QUVxT3FSc0tkcWNoU1FXb2l6Tlk0YmZhel9UNU5Db21hd3ZHZUZhZmtzdGFfV2liR2tjS1VyWU5QQk9iQVBBakpUSWZVTmdQNFZfOW5QaUhZNUx3ZmVGN2Z1clhTX2hieEptZ0NlVE9LZ3pnbWxQNFlMdk01Rk5Gc2VVSEdGenZmQ2pISTFZSWRDa0pZWEo5UmFLTXl1U3huN2NLZzRZcXI5QQ?oc=5) |
| FirstWord Pharma | FDA staff report throws cold water on Capricor's DMD cell therapy bid | 2026-07-27 23:18 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE96Q2M0Q3ZkREljbllFY3RWeXhrTDJGRmQ0OVM2WmN5TTQ0aGswVUJadzBNZHNWSGRmX2U5dDFiTGJvTjBJdnVvUjFSTGQ4VXhYVDhV?oc=5) |
| Business Wire | Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation | 2026-07-27 23:18 | [Source Link](https://news.google.com/rss/articles/CBMiiwJBVV95cUxPUTJxNFBqQlJhVzdGZWJ2MUVhS0I3ZW9RcFFIUWNpRHlZeEZOclotMmhIenBoUFJPU09VV0JQN1pqVjE0ZHVWUldXcTVTRVRkZ2FkemRxb1l1LTFObkU3UVZjY3ZhbnZoZjVvczV0WXRDVVRwc0szOTlJWTd3OHdNQmVTOXdQT1ZfNkV3eG1pMXI0bDRiamFRby1IaEZVT3I4UF9vcHREWWNuYlloZ2J2Vk5hVExUVGdXZGZnSS1lckU4eVVXWFN2eHd1Yl9nWmhWWjhPSmhDdzRSWWdpelhXNXNhS3ZMTDB3c2JObWFHRXUxXzRMcU5pekJuR0RpaHMtblY4MlByM0JJM0E?oc=5) |
| BioWorld News | Adcom ‘cage match’ in store for Capricor? | 2026-07-27 13:08 | [Source Link](https://news.google.com/rss/articles/CBMihgFBVV95cUxPb1EyZG5RTlJXTWtzNk9fUlljZDlCa012WU5vakNOQW1xZnl6U3RSeVlZLUZJd1JpV1RtV0REOC1MaGdkeDZCbzFTUkZoblVjQmNVYVFxOG9jLVlWVGpoNHZKYjRLc1FfaTdrajNLYjlSN1Vqd3QxUjNoZjNoVTMtemVWTXNqdw?oc=5) |
| Intellectia AI | Capricor Provides Update on Deramiocel for DMD Ahead of FDA Meeting | 2026-07-27 13:08 | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxOVUxMODZkNDM4dC1TMU9UaF9jWjZ0ZXBzY3ZGTl9UVjUzLXRnRThqOHpIb2t5SU10TXJMUVliNV9lMjMtWkxBSm0xU2FzREZvXzBNSnB1Z3Z3WVRnMndUSkRibFJwLUJrdlZDWmFOYjdldVJJa0FJSzNrX2h5NG5oN0FSbUZXUWcwNjk3QmctbVFKeUtNT2J2bmZ4MlhheXNWYXNj?oc=5) |
| BioPharma Dive | FDA scientists question Capricor data; Legend CEO steps down | 2026-07-27 13:08 | [Source Link](https://news.google.com/rss/articles/CBMimwFBVV95cUxOcTFaN09vdWxVaERiT2xDdV9jdEs3TWlqaUNfb0I3QXJ1NXU4RHZFNTFYdEF4SFZLXzRXMlNpTHpzQ3BtSUUtb01MU3dlTmozVm5uRzRFeGVLaHJ0dGY2aWExTmtYNnNzYVpkLU91djdkYk1iWDdYdDhYTlBoQXh4N3diU2Q0S3ZDSndEWk14ajE0Z1RzRnJQdkRlVQ?oc=5) |
| Quiver Quantitative | Capricor Therapeutics Provides Update Ahead of FDA Advisory Committee Meeting on Deramiocel BLA for Duchenne Muscular Dystrophy | 2026-07-27 13:08 | [Source Link](https://news.google.com/rss/articles/CBMi8gFBVV95cUxQOXJPNmo2NG1qdkREcFVHZXExNFdESE5BN25Eb2UtMHpIQnFIV1d6WGtMV1BiV2wxcUJBRzVfRVJZT0RtZWtNaGJZVHRSQmtLTGlhM2d3UlMycjZhNDVhdVpsaEdsRTVBb2cwUy0xMmx4dUlBNVhGRXFtZzRqZ2hMcWtGRW5nQ1A2RUFrTEhRTDhjczdDX3EtbE95dWxkSW1SVElFMEgzZ2pySk53WFVXbkV6VDExVlBla1VGMU9YUm9nUHJ5ZENVcGV3UzUyLTNtb0JiVkhxRE4tMkxQRHd1RlVLMzUyMmUzQzRwb09zNFd4UQ?oc=5) |
| Yahoo Finance | How FDA‑Linked HQ and Manufacturing Expansion At Capricor Therapeutics (CAPR) Has Changed Its Investment Story | 2026-07-27 13:08 | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxQTk91U3lkaFBxZWlLN3VFYUJnTzJscjhTbC0yNEs4SDhwVG40V3dvYmpJdHhIUTliNjBzOUtHTnByWkpINXItRmZCY3VYOHRScENjZXQ2N2RwcmY1aWp5eUlFeTJmWVU0eURQYURvWnh4aUVMTk1iT3QwMjN1N1FLYjVMTlF2cmF5YUdMMVZ5XzFob191YmlYXzJhdmZiVDA?oc=5) |
| Pluang | Capricor updates ahead of FDA advisory meeting on Duchenne muscular dystrophy therapy Deramiocel. | 2026-07-27 13:08 | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRHNxMlZYdzJZc0NJVjBYT1doMXgzRnRsNHJQMHNEdkJQZjFQQzJxa3NYcHhCeHFlZVJvRzY5QUVQN25STDNwdU9wNjk0SEVKZjB5dlhoY3ZXNFFoeGhHbEgxeW1JR2xtODBra0lsVFVWWTR5ZXljaEE0M0gzOGRnMEJQTkxqV05MTjh2ZWtTNnJQU1NXUkVMdi03cUR3NU5UdEFXZWVSYk5kZk0?oc=5) |
| simplywall.st | Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel | 2026-07-27 13:08 | [Source Link](https://news.google.com/rss/articles/CBMi6gFBVV95cUxORHdjcElVazlydkRuN3djUm1YNHNTTmlWbVM0YWNUZC1Oc3hDc3VCbWFpMG53U2hiQTBlZEh3MncwRGpXbExEU2U1UFM1RGwyYW55eGtaaWFOc3lMVTZLZjNsaVFKZ0VlTUV0Uk1NNE9oNmg4aGc0LXpMUF85bWNvVWhKSHFkX2JYLThzY2I2Qmlwb2gwWEw0Ul84dk5CaDN4SGlvR2V2UXBKcTFrM2cyc1R4ZzZjMVoxd1FCSVdJdWxZcDhjckd4eDQtY0dGbjBQV0lhMWVWWTJMdG52QlM0VXdid2RWVGpjOUHSAe8BQVVfeXFMTXJfcXZ3cUdJcHBrdmxVZmVMWGRVT1d2Sl9zVl8xY3NtVVFQQXEwWmEwdWltNE0zY2g0VTdoczlDVE9pTFJMWUlXNldDZTBzam1LM19lVXd1MWVza1hBRDJrSEEyUXpVTmZ) |
| WTVB | FDA staff flags concerns for Capricor’s Duchenne heart disease therapy | 2026-07-27 13:08 | [Source Link](https://news.google.com/rss/articles/CBMiogFBVV95cUxNaG1hdXFlRGpfRHRjM2twY21LSkFXSzhGZm5rY2duRmFYWFFPRlVZM19GQmZJclRjNnk1Ym9EdWhId1pXam5LTVRVVWFUQjhnUTV1UDFEdmVKa05VYk1UdTMwc0llWnpfcFdsZUNQcXVWZkhHaG5ldEVMbzdieWFMcjFpSUlUYXFwVGpIaWJCYW1BNjFybERyZ0Vaank0X3ZEdFE?oc=5) |
| MarketBeat | Stock Traders Purchase Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) | 2026-07-27 13:08 | [Source Link](https://news.google.com/rss/articles/CBMi2AFBVV95cUxPOEZBRkF3aW0zWUI0SE1QempZZ3dkTm9jbTFycXY3NTdQeXlqWnd2TlAxX1Zyd2NyTzJ5dXdqaGZMZkliem5WSkl2eTdpZjlwNmk4M25PM1FCaEd5a0V3VkIyYVpsc3VaVl9UR1lmcXZub3pIVkhyVmhzS0NzTXVZMlpoSkJENmRjV184TWp0MDU5WVhMbkRFdEg1X0lUNjJZNnUtanVTckNsRDN0UWJDQ0FuSWZ4Q0tTLXpOTVBKNU9QdjVxY0pBQWpIWVMwd3BzSVdKVkVyTlc?oc=5) |
| Reuters | FDA staff flags data concerns about Capricor's therapy; shares plunge | 2026-07-27 13:08 | [Source Link](https://news.google.com/rss/articles/CBMi0wFBVV95cUxQVnBOS1RYdGpTaVNfVHVYVExxdTl4OGtNX3ZUYTNTYmZjRmdTeEpsdlM5cUhkNW94OE1najhrVEhMVFUyenBJb0ptMElPNG9GcTc3NDJueGEyOG5MS3ZWeFlzdWhvbFRIdlNNWkRWV1VxTGlzX2Y3VGhJcmFMVjNQT0VETFRWekpiSkN0NTY3UkNEcXp1dmd6ZEZYSGhmdE9oXzdOYmh4NEZuYklGUjBBRTM4SVRvOVNxTzNQZUVYLXllRkQtUW1WSm1kcGtJaHF3cHBF?oc=5) |
| Yahoo Finance | Is Capricor Therapeutics (CAPR) Trading At A Discount After Its Lease Deal And FDA Wait? | 2026-07-27 13:08 | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxPNzd3X3VGRk9sREdmSjNwWjhFT3gtSVlKck1YdjU1LVYtZ001cS1JSjFRZUZmVmxXQTRZLWI5WW9FOUlRRlZZc19NSDF1TFdSbFB4c1NlQ182aUJOTW50Zk5HZWpuSGc3Q0FzX190bkJxT195WWUtNWg3aHZwMXQzZWUzSVhOZnJmR3pYTm9GSHlwTjJEOElldFJUUDJlTG9OZ2pqUkFJZw?oc=5) |
| STAT | Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug | 2026-07-27 13:08 | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTWt4LUgxVEFrN0dBV0RCa0drek85eWJJSlozMHBJamRuVVd1b2RCS1g5OVlDcThhRFd4U2dNNmFtdDQzcWJVdnN6OVhEVURSUmtHNnRLNFlqMFFPM2FkNXhIYjFRX2F3U2xkR0lETUdoOV8tQzdNVjFpU21XTHlmS0xic216ckJsdnU3RDhCbjBzVUVqSUhSRlU2emtfZ0pXRFpJTDZ6Zlh6UQ?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-07-27/ahead-of-hearing-fda-questions-the-efficacy-of-capricor-s-duchenne-drug*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*